11 February 2021: Clinical Research
Risk Factors of Coronavirus Disease 2019-Related Mortality and Optimal Treatment Regimens: A Retrospective Study
Yuehong Wang 1BC* , Shuang Yao 2CDEF* , Xiaoling Liu 3BDEF* , Yinghao Cao 4ABCEF , Yaling Wang 5BF* , Mao Xie 6AEF*DOI: 10.12659/MSM.926751
Med Sci Monit 2021; 27:e926751
Table 6 The factors associated with survival of COVID-19 patients by univariate and multivariate cox regression analysis.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| HR | (95% CI) | P | HR | (95% CI) | P | |
| Age | 1.092 | 1.036–1.150 | 0.001 | 1.319 | 1.115–1.561 | 0.001 |
| BMI | 1.336 | 1.112–1.607 | 0.002 | 1.344 | 1.014–1.783 | 0.040 |
| WBC | 1.019 | 0.999–1.039 | 0.061 | |||
| NEU | 1.141 | 1.068–1.219 | 0.910 | 0.748–1.107 | 0.346 | |
| PT | 1.213 | 1.045–1.407 | 0.011 | 0.489 | 0.271–0.884 | 0.018 |
| APTT | 1.051 | 0.983–1.125 | 0.147 | |||
| AST | 1.008 | 0.989–1.026 | 0.414 | |||
| TBIL | 1.044 | 1.015–1.073 | 0.002 | 1.063 | 1.006–1.124 | 0.031 |
| DBIL | 1.125 | 1.050–1.206 | 0.001 | 0.869 | 0.693–1.091 | 0.226 |
| CRE | 1.005 | 1.000–1.010 | 0.071 | |||
| BUN | 1.074 | 1.025–1.125 | 0.003 | 1.123 | 0.978–1.289 | 0.099 |
| H-CRP | 1.008 | 1.002–1.013 | 0.004 | 1.014 | 1.003–1.025 | 0.013 |
| Disease severity | ||||||
| Severe | 2.438 | 0.253–23.516 | 0.441 | 2.19 | 0.056–86.278 | 0.676 |
| Extremely severe | 13.395 | 1.773–101.175 | 0.012 | 40.8 | 0.551–3023.150 | 0.091 |
| Shock | 11.726 | 3.373–40.760 | 0.001 | 34.713 | 2.596–464.133 | 0.007 |
| ARDS | 11.220 | 2.573–48.915 | 0.013 | 46.252 | 1.504–1422.171 | 0.028 |
| Kidney injury | 5.233 | 1.823–15.016 | 0.002 | 4.380 | 0.052–366.380 | 0.513 |
| Acute heart injury | 4.533 | 1.600–12.840 | 0.004 | 0.201 | 0.004–11.385 | 0.436 |
| Secondary bacterial pneumonia | 2.320 | 0.901–5.976 | 0.081 | |||
| Antiviral therap | 0.221 | 0.084–0.577 | 0.002 | 6.753 | 0.449–101.645 | 0.167 |
| Oseltamivir | 0.283 | 0.088–0.913 | 0.055 | |||
| Arbidol hydrochloride | 0.297 | 0.040–2.227 | 0.238 | |||
| Anti-HIV drugs | – | – | 0.992 | |||
| CK | ||||||
| Decreased | 1.198 | 0.154–9.323 | 0.863 | |||
| Increased | 1.271 | 0.413–3.910 | 0.675 | |||
| CKMB | 2.303 | 0.907–5.848 | 0.079 | |||
| Other treatment | 0.264 | 0.104–0.674 | 0.005 | 0.053 | 0.003–0.890 | 0.041 |
| Anti-infection therapy | 5.442 | 1.227–24.142 | 0.026 | 0.842 | 0.037–19.383 | 0.914 |
| Gammaglobulin therapy | 0.173 | 0.040–0.748 | 0.019 | 1.736 | 0.202–14.894 | 0.615 |
| HR – hazard ratio; CI – confidence interval; BMI – body mass index; WBC – white blood cell; NEU – neutrophil; PT – prothrombin; APTT – activated partial thromboplastin time; AST – glutamic oxaloacetylase; TBIL – total bilirubin; DBIL – direct bilirubin; CRE – creatinine; BUN – urea nitrogen; H-CRP – hypersensitive C-reactive protein; ARDS – acute respiratory distress syndrome; CK – creatine kinase; CKMB – creatine kinase isomer-MB. | ||||||